Author Archives: Mark Taylor

Mark Taylor

About Mark Taylor

Mark Taylor is an independent health care journalist based near Chicago. Taylor was legal affairs reporter for Modern Healthcare magazine and writes for newspapers, as well as Medicare NewsGroup and Hospitals & Health Networks. He is a former Kaiser Media Fellow and a founding member of AHCJ.

Health economist Reinhardt, 80, was longtime friend to AHCJ

Uwe Reinhardt was a keynote speaker at Health Journalism 2009.

Uwe Reinhardt was a keynote speaker at Health Journalism 2009, where he argued that health care is the best investment to revive the United States from recession.

Health care economist and Princeton University professor Uwe Reinhardt, 80, a German émigré and a longtime friend of the Association of Health Care Journalists, died on Tuesday, according to multiple news outlets.

Reinhardt, who earned degrees from the University of Saskatchewan and Yale University, was a giant in his field of health care economics.

Continue reading

Examining efforts to lower cost of caring for seniors at home

Photo by Boris Bartels via Flickr

It’s long been known that 5 percent of all Medicare patients account for more than half of Medicare spending.

In addition, the top 1 percent of the sickest and most vulnerable Medicare patients consume 23 percent of Medicare resources, largely because of the severity of their illness but also because their conditions frequently are not managed well. Repeatedly they travel a painful journey among hospital emergency departments, nursing homes and hospital readmissions, in the process racking up huge medical bills, exposing themselves to hospital-acquired infections and bedsores. In the process, they often lose control of their lives. Continue reading

Common respiratory virus often flies under diagnostic radar, especially for seniors

Photo: Alyssa L. Miller via Flickr

Photo: Alyssa L. Miller via Flickr

While waiting for a shuttle bus at the annual meeting of the Gerontological Society of America in Orlando, I met a fellow conference attendee who worked for a drug company. When he mentioned his company was researching a vaccine for a viral infection called respiratory syncytial virus, commonly known as RSV, I had to scratch my head.

I stupidly thought it was one of those recently concocted pseudo-conditions drug companies occasionally tout to market new products. Continue reading